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Abstract  
Ipratropium bromide (a non-selective muscarinic antagonist) is widely prescribed for the 
treatment of Chronic Obstructive Pulmonary Disease (COPD). Analyses of COPD patients, 
with underlying ischaemic heart disease (IHD), receiving anticholinergics, have indicated 
increased risk of severity and occurrence of cardiovascular events (including myocardial 
infarction, (MI)). The present study explored whether ipratropium bromide induces 
myocardial injury in non-clinical models of simulated myocardial ischaemia/reperfusion 
injury. Adult Sprague Dawley rat hearts/primary ventricular myocytes were exposed to 
simulated ischaemia/hypoxia prior to administration of ipratropium at the onset of 
reperfusion/reoxygenation. Infarct to risk ratio and cell viability was measured via triphenyl 
tetrazolium chloride staining and thiazolyl blue tetrazolium bromide (MTT) assay. The 
involvement of apoptosis and necrosis were evaluated by flow cytometry. Mitochondrial-
associated responses were detected by tetramethyl rhodamine methyl ester (TMRM) 
fluorescence and myocyte contracture. Ipratropium (1x10-11 M - 1x10-4 M) significantly 
increased infarct/risk ratio and decreased cell viability, in a dose-dependent manner. 
Increased levels of necrosis and apoptosis were observed via flow cytometry, accompanied 
by increased levels of cleaved caspase-3 following ipratropium treatment. Levels of 
endogenous myocardial acetylcholine were verified via use of an acetylcholine assay. In 
these experimental models, exogenous acetylcholine (1x10-7 M) showed protective 
properties, when administered alone, as well as abrogating the exacerbation of myocardial 
injury during ischaemia/reperfusion following ipratropium co-administration. In parallel 
experiments, under conditions of myocardial ischaemia/reperfusion, similar injury was 
observed following atropine (1x10-7 M) administration. These data demonstrate for the first 
time in a non-clinical setting that ipratropium exacerbates ischaemia/reperfusion injury via 
apoptotic and necrotic associated pathways.  
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Introduction 
Ipratropium bromide ([8-methyl-8-(1-methylethyl)- 8-azoniabicyclo[3.2.1] oct-3-yl] 3-hydroxy-
2-phenyl-propanoate, ipratropium), a non-selective muscarinic receptor antagonist (Wood et 
al., 1995), has been widely prescribed for management of Chronic Obstructive Pulmonary 
Disease (COPD) since 1987 (Restrepo, 2007) and more recently as adjunctive emergency 
treatment for acute asthma (Aaron, 2009). The antagonist action of ipratropium at the 
muscarinic receptors in the lungs (primarily M3 subtype) inhibits acetylcholine induced 
reflexes, leading to smooth muscle relaxation. This facilitates airflow by alleviating the 
bronchospasm symptomatic of COPD exacerbations (Tranfa et al., 1995; Restrepo, 2007). 
There are five known subtypes of muscarinic receptors (mAChRs), distributed across a 
plethora of tissues. MAChRs are responsible for a multitude of neuronal and non-neuronal 
actions (Caulfield and Birdsall, 1998; Resende and Adhikari, 2009). Within mammalian 
pulmonary systems, the M1, M2, M3 and M4 subtypes are all differentially expressed (Wessler 
and Kirkpatrick, 2008). Although M2 receptors constitute the majority of mAChRs in the 
myocardium, it has been shown that M1 and M3 receptors are also present. In particular, it 
has been shown that activation of M3 receptors may be associated with activation of pro-
survival signalling cascades following ischaemia/reperfusion (I/R) (Yue et al., 2006; Wang et 
al., 2007). 
In addition to airflow obstruction, there is increasing evidence that COPD contributes to 
systemic pathologies, including Ischaemic Heart Disease (IHD) (Macnee et al., 2008). 
Underlying IHD also represents the highest risk factor for death by myocardial infarction (MI) 
in COPD sufferers (Zielinski et al., 1997). It is estimated that approximately 22% of patients 
with COPD suffer from underlying IHD.  
Within the past decade, despite much controversy, numerous studies have indicated 
cardiovascular risks associated with COPD patients receiving anticholinergic therapies 
(Singh et al., 2008). However, despite the known co-morbidities, to our knowledge there 
have been no non-clinical investigations to date to assess the effects of anticholinergic 
compounds, such as ipratropium, in the setting of simulated IHD or MI. Further to this, Shaik 
et al (2012) have recently demonstrated that ipratropium is capable of eliciting suicidal 
erythrocyte death (eryptosis) via a mechanism due to stimulation of increased cytosolic Ca2+ 
activity (Shaik et al., 2012). Despite differences between eryptosis and apoptosis, which only 
occurs in nucleated cells, both of these processes can be initiated by increases in Ca2+ 
concentration, indicating that ipratropium may have the ability to also trigger apoptosis. 
Conversely, endogenous muscarinic activation by acetylcholine has revealed cytoprotective 
properties against various cellular insults, including conditions of myocardial I/R injury (Budd 
et al., 2003; De Sarno et al., 2003; Critz et al., 2005; Resende and Adhikari, 2009; Li et al., 
2011). 
The exact mechanism by which I/R injury occurs remains a matter of some debate, however 
it is known that myocyte loss occurs via both apoptosis and necrosis (Kung et al., 2011).  
The key determinant for initiation of intrinsic apoptosis is mitochondrial outer membrane 
permeabilisation (MOMP), thereby initiating a caspase-dependent apoptotic cascade 
(Dewson and Kluck, 2009). Acetylcholine has been shown effective in protecting the 
myocardium against hypoxia induced apoptosis (Kim et al., 2008; Liu et al., 2011) by 
regulation of Bcl-2 family proteins and caspase-3, a pivotal caspase in the machinery leading 
to apoptotic death. In the context of a healthy cell, caspases exist as inert zymogens; 
however, during apoptosis proteolytic cleavage renders them active, permitting caspase-
dependent apoptosis. 
During I/R, increases of intracellular of Ca2+ and oxidative stress lead to rapid ATP depletion, 
thereby causing rupture of the outer mitochondrial membrane. This facilitates the influx of 
toxic mitochondrial proteins into the cytosol, thus initiating apoptosis (Hausenloy et al., 2002;  
Halestrap and Pasdois, 2009) as well as myocyte death by necrosis (Yellon and Hausenloy, 
2007) which occurs via the resultant collapse of mitochondrial function after disturbance of 
mitochondrial membrane potential (Crompton, 1999). 
The purpose of this study was to determine the effect of ipratropium bromide administration 
in the context of I/R in isolated perfused rat heart (1x10-9 M – 1x10-6 M) and simulated I/R in 
a primary rat cardiac myocyte model (1x10-11 M – 1x10-4 M). Acetylcholine (1x10-7 M) was 
also administered concomitantly with ipratropium to ascertain whether the observed effects 
of ipratropium were due to a specific action on the muscarinic receptors. The involvement of 
apoptosis, necrosis and cleaved caspase-3 were evaluated by flow cytometry. Additional 
experiments were undertaken via the use of Z-DEVD-FMK (DEVD, 7x10-9 M), a potent 
caspase-3 inhibitor, to confirm whether the effects of ipratropium were dependent on 
caspase-3 activation. Further to this, a cardiomyocyte model of oxidative stress was 
employed to assess ipratropium’s effect on mitochondrial membrane potential and rigor 
contracture. 
Materials and Methods 
Animals 
Adult male Sprague-Dawley rats (350g ± 50g body weight) were bred in-house (Coventry 
University, Coventry, UK). All animals resided under the same conditions, received humane 
care and a standard diet.  Procedures were carried out in accordance with the Guidance on 
the Operation of the Animals (Scientific Procedures) Act 1986 (The Stationary Office, 
London, UK). 
Experimental design and isolated perfused heart model of I/R 
For the isolated perfused heart (Langendorff) model of I/R, rats were sacrificed by cervical 
dislocation prior to excision of the heart. The heart was immediately placed in ice cold Krebs-
Heinsleit buffer (1.18x10-1 M NaCl, 2.5x10-2 M NaHCO3, 4.8x10-3 M KCl, 1.2x10-3 M MgSO4, 
1.2x10-3 M KH2PO4, 1.2x10-2 M Glucose, 1.7x10-3 M CaCl22H2O) and mounted on a 
Langendorff apparatus for retrograde perfusion with Krebs-Heinsleit buffer (maintained at 
37oC, pH 7.4 and saturated with 95% O2 5% CO2). Following 20 min stabilisation, ischaemia 
was induced via insertion of a surgical suture under the left descending coronary arteries, 
through which the ends were passed through a plastic tube to form a snare. The snare was 
tightened to induce regional ischaemia, for 35 min, after which releasing the threads initiated 
reperfusion. All drugs were added at the onset of, and throughout, reperfusion which lasted 
120 min. To delineate the ischaemic from the non-ischaemic area, at the end of reperfusion 
the coronary arteries were re-ligated and the heart perfused with a 0.25% Evans blue saline 
solution. This enabled visual differentiation between the non-ischaemic area (which stained 
dark blue) and the ischaemic area, which did not stain. The hearts were immediately stored 
at -20oC. Once frozen, hearts were transversely sliced into 2 mm thick sections and 
incubated at 37oC in a phosphate buffer solution containing 1% 2,3,5-triphenyltetrazolium 
chloride (TTC). For preservation and development of the staining, hearts were placed in a 
10% formalin solution for 4 hours before analysis. After staining, the viable tissue in the 
ischaemic area appeared red (tetrazolium positive) distinguishing it from the infarct tissue 
which was pale and white (tetrazolium negative). The heart slices were compressed 
between two Perspex sheets and the viable and infarct tissue from the risk zone were traced 
onto acetate film. Computerised planimetry (using Image Tool as developed by the 
University of Texas Health Science Centre at San Antonio, UTHSCSA) allowed the 
percentage of infarct tissue within the ischaemic area to be calculated (I/R%). 
Determination of haemodynamic function 
Following mounting on the Langendorff apparatus, the left atrium was removed, allowing 
insertion of a fluid-filled latex balloon, inflated to constant diastolic pressure of 5-10 mmHg, 
into the left ventricle. A physiological pressure transducer connected to a Powerlab (AD 
Instruments Ltd. Chalgrove, UK) via a bridge amp facilitated the regular measurement of left 
ventricular developed pressure (LVDP, mmHg) and heart rate (HR, bpm). Coronary flow 
(CF, ml.min-1) was measured by collecting the perfusate at regular time intervals. 
Measurements of all three haemodynamic parameters were taken every 5 min during 
stabilisation and ischaemia and every 15 min throughout reperfusion. A significant drop in 
LVDP and CF following the initiation of ischaemia compared with LVDP and CF at 
stabilisation was necessary to ensure that ischaemia had been performed appropriately 
(data not shown), 
Rat cardiac myocyte isolation protocol 
Adult rat myocytes were isolated by enzymatic digestion of the extracellular matrix (Maddock 
et al., 2002). Briefly, following sacrifice by cervical dislocation, rat hearts were quickly 
excised and mounted on a modified Langendorff apparatus for retrograde perfusion with a 
modified Krebs-Ringer’s buffer (KRB) (2.0x10-2 M NaHCO3, 1.16x10-1 M NaCl, 1.2x10-3 M 
KH2PO4, 5.4x10-3 M KCl, 4.0x10-4 M MgSO4.7H2O, 1.2x10-3 M glucose, 2.0x10-2 M taurine, 
5.0x10-3 M sodium pyruvate, oxygenated with 95% O2 5%CO2, pH 7.4 and maintained at 37 
oC). After 2 min perfusion the buffer was switched to KRB supplemented with 0.075% 
Worthingtons Type II Collagenase and 4.4x10-6 M CaCl2, which formed the digestion buffer. 
Hearts were perfused with the digestion buffer for 7 min prior to removal from the apparatus 
and separation of the ventricles from the atria. The ventricular tissue was then minced and 
further incubated in the digestion buffer until enzymatic dissociation was complete. Myocytes 
were filtered through a nylon mesh, washed with restoration buffer (1.16x10-1 M NaCl, 
2.5x10-2 M NaHCO3, 5.4x10-3 M KCl, 4.0x10-4 M MgSO4.7.H2O, 1.0x10-2 M glucose, 2.010-2 
M taurine, 5x10-3 M sodium pyruvate, 9.0x10-4 M Na2HPO4.12H2O, 1% BSA and 1% Pen-
Strep, at 37 oC and pH7.4) and maintained at 37oC. 
Acetylcholine assay 
Choline/Acetylcholine Assay Kit (Abcam, UK) was used to determine cell lysate 
acetylcholine levels in myocytes under normoxic conditions and those subjected to the H/R 
protocol. Half the myocytes from isolations used were kept under normoxic conditions, 
whereas the other half was subjected to the H/R protocol. The assay was carried out in 
accordance with the manufacturer’s instruction. The assay was conducted in the absence 
and presence of acetylcholinesterase in order to identify values of total and free choline to 
establish the concentration of acetylcholine in myocyte lysates. 
MTT Cell Viability assay 
Ventricular myocytes were counted and resuspended in Esumi ischaemic buffer (Esumi et 
al., 1991), prior to 4 hours hypoxia. To initiate reoxygenation, myocytes were randomly 
assigned to drug treatment groups and resuspended at 1x105cells.ml-1 in drug treated 
restoration buffer. Reoxygenation lasted 2 hours before all wells were treated with 20µl 3-
(4,5-Dimethyl-2-thiazolyl)-2,5-diphenyl-2H-tetrazolium bromide (MTT) (5mg.ml-1, in PBS) and 
incubated, in the dark, for a further 2 hours. 100 µl Lysis buffer (20% SDS in 50% N-N-
Dimethylformamide) was administered to all groups and further incubated on an orbital 
shaker, in the dark, overnight, prior to colorimetric analysis at 450 nm. The 
hypoxia/reoxygenation (H/R) protocol was considered to have been successful when there 
was an approximate 40% drop in viability in the control myocytes in comparison with 
myocytes not subjected to the H/R protocol (normoxic group). 
Flow cytometric analysis for cleaved caspase-3 activity and cell death assay 
Following hypoxia, as outlined above, myocytes were reoxygenated in the presence of the 
corresponding drugs for their treatment group for 4 hours. Myocytes were transferred to 
labelled, 1.5 ml microfuge tubes and, following the manufacturer’s (Cell Signaling 
Technology) instruction, stained using Caspase-3 (Asp175) with Alexa Fluor® 488 
Conjugate and 10,000 myocytes per sample were analysed using the FL-1 channel. Flow 
cytometric analysis was carried out using a FACS CaliburTM flow cytometer. In order to carry 
out the cell death assay, Vybrant® Apoptosis Assay Kit #10 (Life Technologies Ltd, Paisley, 
UK) was implemented, according to the manufacturer’s instruction. This allowed for 
differentiation between viable, apoptotic and necrotic myocytes on the basis of respective 
staining with resazurin-C12, Annexin V or SYTOX® Green. Stained cells were analysed via 
flow cytometry whereby the different myocyte populations could be distinguished from one 
anothe. 10,000 myocytes were analysed per sample on the FL-1, 3 and 4 channels. 
Oxidative Stress Model Protocol 
In total, seven animals were used, from which between 10 and 15 myocytes were measured 
for each experimental group. Ventricular myocytes were plated onto laminin coated petri 
dishes (35 mm diameter) and incubated for ≥2 hours to allow adhesion of the cells. The 
supernatant, including affluent cells was aspirated and discarded. The adhered myocytes 
were incubated in microscopy buffer (modified Krebs-Ringer’s buffer with 1.0x10-2 M HEPES 
and 1.2x10-6 M CaCl2) containing 3x10-6 M tetramethylrhodamine methyl ester (TMRM) for 
15 min. Cells were washed with microscopy buffer and randomly assigned to one of the drug 
treatment groups and incubated for a further 15 min with 1x10-9 M – 1x10-6 M ipratropium ± 
acetylcholine (1x10-7 M) and atropine (1x10-7 M) ± acetylcholine (1x10-7 M). To view and 
analyse myocytes, dishes were placed on the stage of a Zeiss 510 CLSM confocal 
microscope equipped with 20x objective lens (NA 1.3) and a heated chamber. A 585 nm 
long pass filter allowed detection of TMRM when viewing the cells. Recording and analysis 
was facilitated by use of the Zeiss software package, LSM 2.8. Laser stimulation via 543 nm 
emission line of HeNe laser was used to induce oxidative stress. Prior to laser stimulation, 
the cationic TMRM selectively localises in the negatively-charged inner-membrane of the 
mitochondrion in a membrane potential-dependent manner. Laser stimulation initiates 
photodecomposition of TMRM thus generating mitochondrial reactive oxygen species, 
leading to disruption of the mitochondrial membrane. Depolarisation (Dep) was measured as 
the time at which the TMRM started to become evenly distributed throughout the cell and is 
indicative of loss of mitochondrial membrane potential. Subsequent hypercontracture (Hyp) 
of myocytes occurs shortly afterwards. The time to both Dep and Hyp were recorded. 
Data analysis 
All data are expressed as the mean ± SEM. ANOVA and Fisher’s protected least significant 
difference test were used to determine statistical differences among experimental groups, 
via use of SPSS Statistics 17.0. A value of p<0.05 was considered to be statistically 
significant. 
Drugs and materials 
Ipratropium bromide, atropine (both Tocris bioscience, Bristol, UK) and acetylcholine 
chloride (SIGMA, Poole, UK) were dissolved in ddH2O prior to dilution for experimental use. 
Z-DEVD-FMK (Tocris Cookson, Bristol, UK) was dissolved in DMSO prior to dilution for 
experimental use. TTC and Evans blue were both purchased from SIGMA (Poole, UK). The 
antibodies for Cleaved Caspase-3 (Asp175) with Alexa Fluor® 488 Conjugate was obtained 
from New England Biolabs (Ipswich, UK). Vybrant® Apoptosis Assay Kit #10 was purchased 
from Life Technologies Ltd (Paisley, UK) and Choline/Acetylcholine Assay Kit from Abcam 
(Bristol, UK). 
  
Results 
Effect of Ipratropium and Acetylcholine on I/R 
The results from 54 successful experiments were included and are presented in Figures 1 
and 2. Figure 1 shows the observations from isolated perfused heart experiments where 
ipratropium (1x10-9 – 1x10-6 M) was administered at reperfusion. This data showed that 
ipratropium increases the development of infarct in a dose-responsive manner. Infarct/Risk 
(%) (I/R (%)) was statistically different from control hearts (51.8 ± 3.0%) at concentrations of 
1x10-8 M and above (Table 1, A). A submaximal concentration of ipratropium (1x10-7 M) was 
used in all subsequent experiments. The results presented in Figure 2 show the effect of 
acetylcholine (1x10-7 M) administration at reperfusion. Acetylcholine significantly reduced 
infarct size in comparison with the control (42.7 ± 2.9% (ACh, 1x10-7 M) vs. 51.8 ± 3.0% 
(control), p<0.05). The observed increase in infarct size due to ipratropium treatment was 
significantly attenuated when administered in conjunction with acetylcholine (Table 1, B). 
Atropine (1x10-7 M) administration at reperfusion was also shown to significantly increase 
infarct development in comparison with the control (58.64 ± 1.7% (Atr, 1x10-7 M) vs. 51.8 ± 
3.0% (control), p<0.05), which was also significantly attenuated upon acetylcholine 
administration (Table 1,C). 
 
Identification of Acetylcholine levels in isolated rat cardiac myocytes 
Endogenous levels of acetylcholine in primary cultures of rat cardiac myocytes were 
established using an acetylcholine assay kit to identify the concentration of acetylcholine in 
myocyte lysates. This enabled measurement of free and total choline, allowing quantification 
of acetylcholine levels. Under normoxic conditions (Fig.3, A & B), levels of acetylcholine 
were found to be 1.7x10-9 M. In cell lysates from myocytes subjected to the H/R protocol 
(Fig.3, C & D), the concentration of acetylcholine was observed as 1.3x10-9 M. 
 
Effect of Ipratropium on adult rat cardiac myocyte viability 
MTT (3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) is reduced to purple 
formazan by mitochondrial dehydrogenase, and therefore provides an assay for cellular 
viability. Figure 4 shows percentage change in MTT reductase activity, indicative of myocyte 
viability, of the control in comparison with myocytes administered ipratropium or atropine 
(1x10-11 M – 1x10-6 M). Administration of ipratropium or atropine at the onset of 
reoxygenation produced a significant reduction in cell viability in a dose responsive manner 
(Table 3). The cell viability assay was conducted in the presence and absence of 
acetylcholine ± ipratropium or atropine (Figure 5). Treatment with acetylcholine significantly 
increased cell viability (108.0 ± 4.6%, (ACh, 1x10-7 M) vs. 100 ± 0.0% (control), p<0.05) in 
comparison with the control. In the group treated concomitantly with ipratropium and 
acetylcholine, cell viability was significantly increased in comparison with myocytes treated 
with ipratropium alone (88.7 ± 4.5% (Ip + Ach) vs. 73.0 ± 2.1% (Ip, 1x10-7 M), p<0.05). A 
significant decrease in myocyte viability was observed in the group treated with atropine 
(81.3 ± 8.3% (Atr, 1x10-7) vs. 100 ± 0.0% (control), p<0.05). In comparison with the group 
treated with both atropine and acetylcholine, there was a small increase in viability in 
comparison with the atropine group, however, this was statistically insignificant. 
 
Effects of ipratropium on apoptosis and necrosis 
Additional experiments were conducted to identify whether the observed ipratropium induced 
increase in I/R (%) and reduction in cell viability was due to apoptosis or necrosis. Viable 
(data not shown), necrotic and apoptotic myocytye populations were recorded via flow 
cytometry from cardiac myocytes exposed to ipratropium treatment (1x10-9 M – 1x10-6 M) 
throughout reoxygenation (Figure 6). Apoptosis and necrosis were estimated by Annexin V 
and SYTOX® Green positive myocytes, respectively. All concentrations of ipratropium tested, 
caused a significant increase in apoptosis (Annexin V positive) in comparison with the 
untreated control (100 ± 0.0, control vs. 169.8 ± 19.7 (1x10-9 M), 160.9 ± 23.3 (1x10-8 M), 
139.9 ± 18.1 (1x10-7 M) and 153.1 ± 17.9 (1x10-6 M), all p<0.05. In addition ipratropium 
administration caused a significant increase in necrosis (SYTOX® Green positive) above the 
control group at 1x10-8 M, 1x10-7 M and 1x10-6 M ipratropium (100 ± 0.0, control vs. 142.6 ± 
15.5 (1x10-8 M), 141.6 ± 23.9 (1x10-7 M) and 140.9 ± 17.7 (1x10-6 M), all p<0.05). 
Effect of ipratropium treatment on cleaved caspase-3 levels following simulated 
iscaemia/reperfusion 
Having established an increase in apoptotic death, following ipratropium administration, the 
involvement of cleaved caspase-3 was evaluated by flow cytometry. The data are presented 
in Figure 7 (B). This shows that exposure of ventricular cardiac myocytes to ipratropium 
throughout reoxygenation is associated with an increase in levels of cleaved caspase-3 (Asp 
175), an effect which was significant when ipratropium was administered at 1x10-7 M and 
1x10-6 M (100 ± 0.0, control vs. 128.7 ± 5.82 (1x10-7 M), p<0.05, 147.5 ± 12.8 (1x10-6 M), 
p<0.01. Addition of acetylcholine (1x10-7 M) (Figure 7 (C)) significantly decreased the level of 
cleaved caspase-3 compared with the control (70.2 ± 10.5 vs. 100 ± 0.0 (control), p<0.05). 
Administration of atropine also produced a significant increase in caspase-3 levels in 
comparison with the control (119.8 ± 6.73 vs. 100 ± 0.0 (control), p<0.05). However, the co-
administration of ipratropium or atropine with acetylcholine produced effects which, although 
showed a decrease in cleaved caspase-3, were statistically insignificant in comparison with 
the respective groups treated with ipratropium or atropine alone. 
In addition, the involvement of caspases in myocardial cell death following ipratropium 
treatment was assessed in perfused hearts via the administration of Z-DEVD-FMK (DEVD, 
7x10-9 M, a potent caspase-3 inhibitor) in conjunction with ipratropium (1x10-7 M) at the 
onset of reperfusion. These data are presented in Figure 8. Administration of DEVD 
produced a significant reduction in I/R (%) in comparison with the untreated control (51.8 ± 
3.0%, control vs. 29.7 ± 4.7%, DEVD, p<0.01). As previously demonstrated, the group 
treated with 1x10-7 M ipratropium induced a significant increase in infarct/risk (%) of 75.1 ± 
4.3%. In the group treated with both DEVD and Ipratropium, infarct development was 
significantly inhibited in comparison with both the untreated control and ipratropium (1x10-7 
M) treatment group (36.7 ± 3.7% (DEVD + Ip), vs. 51.8 ± 3.0% and 75.1 ± 4.3% respectively, 
both p<0.01). 
Involvement of mitochondria following ipratropium administration in a model of oxidative 
stress 
Having identified involvement of both apoptotic and necrotic myocyte death following 
ipratropium administration, a myocyte model of oxidative stress was employed to determine 
the action of ipratropium on mitochondria. Figure 9 (A) portrays the time points which were 
visualised and measured (depolarisation and hypercontracture) via confocal microscopy. 
The administration of ipratropium (1x10-8 M and 1x10-7 M) significantly decreased the time 
taken for depolarisation to occur in comparison with the control group (201.2 ± 9.9 s, control 
vs. 173.8 ± 14.6 s (1x10-8 M) and 147.5 ± 17.5 s (1x10-7 M), p<0.05, Figure 9 (B)). The 
subsequent time to hypercontracture was also recorded, as presented in Figure 9 (C). As 
with depolarisation, there was a significant decrease in hypercontracture following 
ipratropium (1x10-8 M and 1x10-7 M) administration (585.3 ± 33.9 s, control vs. 460.5 ± 19.0 
s (1x10-8 M) and 455.2 ± 15.3 s (1x10-7 M), p<0.05). In order to determine whether 
acetylcholine elicited protection via a mechanism involving mitochondria, the same protocol 
in the presence of acetylcholine ± ipratropium was conducted. Acetylcholine administration, 
alone (277.2 ± 26.1 s, p<0.01), and in conjunction with ipratropium (237.0 ± 9.4 s, p<0.05), 
was capable of significantly delaying time to depolarisation in comparison with the control 
(Figure 9 (D)). The subsequent time to hypercontracture was also recorded (Figure 9 (E)). 
These results mirrored those from depolarisation (455.1 ± 15.2 s in Ip, p<0.01, 572.9 ± 23.4 
s in ACh, p<0.05 and 547.7 ± 12.1 s in Ip + ACh vs. 550.2 ± 1.7 s in control), with the 
exception that statistically there was no difference between the control and Ip + ACh treated 
groups. 
  
Discussion 
The major finding of this work is that ipratropium significantly exacerbates myocardial injury 
under in vitro conditions of simulated myocardial ischaemia/reperfusion and oxidative stress. 
This was observed as an increase in infarct size (I/R%) in the isolated perfused rat heart and 
as a decrease in myocyte viability in primary rat ventricular myocytes, established via a 
decrease in MTT reductase activity. The present study also demonstrates the ability of 
acetylcholine to abrogate the exacerbation of I/R injury in these two models. This accords 
with previous studies which have shown muscarinic activation is cytoprotective following an 
ischaemic insult (Qin et al., 2003; Davidson et al., 2006; Zhao et al., 2010). Interestingly, in 
the current study, acetylcholine was capable of attenuating some of the observed 
ipratropium induced injury when ipratropium and acetylcholine were co-administered. This 
indicates that the inhibitory action of ipratropium, as a competitive antagonist, at the cardiac 
muscarinic receptors is responsible for eliciting the observed injury. 
In the current study the presence of acetylcholine in in vitro tissue was confirmed, as shown 
by Doležal and Tuček (1983), via use of the acetylcholine assay. However, ipratropium 
administration was sufficient to significantly increase myocardial injury in the absence of 
exogenous acetylcholine (1x10-7 M). Previous work has shown that acetylcholine protects 
the myocardium following I/R (Li et al., 2011) by permitting activation of reperfusion injury 
salvage kinase (RISK) signalling cascades (Shanmuganathan et al., 2005; Tsang and 
Yellon, 2005), maintenance of gap junctional integrity (Yue et al., 2006; Zhao et al., 2010) 
and prevention of apoptosis (Kim et al., 2008; Liu et al., 2011). This study supports the 
protective properties of acetylcholine and postulates that the administration of ipratropium is 
sufficient to compete with endogenous acetylcholine, which accounts for the observed 
inhibition of acetylcholine induced myocardial protection following I/R.  
The parallel studies using atropine have generated supporting evidence for muscarinic 
involvement as through this work increases in infarct development and cleaved capase-3 
levels as well as decreased myocyte viability were observed with atropine administration. It 
was also demonstrated that acetylcholine was capable of compensating for some of the 
observed atropine induced injury when administered in conjunction with atropine. 
Ipratropium is synthetic atropine derivative (Wood et al., 1995), and both drugs are non-
selective muscarinic antagonists. The ability for both atropine and ipratropium to exacerbate 
myocardial injury in the experimental models presented here implies a common mechanism 
of action of the two drugs which reinforces the theory that muscarinic signalling may be 
involved in ipratropium induced exacerbation of myocardial injury. 
During reperfusion, myocyte loss can occur through both apoptosis and necrosis (Kung et 
al., 2011). Administration of ipratropium was associated with an increase in both necrotic 
and apoptotic myocyte death in comparison with the untreated group.  
Furthermore, it was demonstrated that ipratropium administration, at the onset of 
reoxygenation in isolated rat cardiac myocytes, was associated with an increase in levels of 
cleaved caspase-3. Caspase-3 is an essential effector caspase in the caspase-dependent 
apoptotic signalling cascade. Caspases exist as zymogens but are only cleaved to form 
active enzymes following the onset of apoptosis. Significant increases in cleaved caspase-3 
levels were observed following ipratropium administration, thereby indicating that ipratropium 
exacerbation of myocardial injury involves a caspase dependent apoptotic component. This 
was further supported by the isolated perfused heart studies using ipratropium and Z-DEVD-
FMK (DEVD), an irreversible inhibitor of caspase-3 activation. These data identified that the 
observed ipratropium induced increase in I/R (%) was abrogated when administered in 
conjunction with DEVD. 
The levels of caspase-3 in the acetylcholine treatment group were significantly lower than in 
the control group, indicating that acetylcholine myocardial protection is, in part, due to a 
reduction in apoptosis. This is also supported by other studies where acetylcholine induced 
cardioprotection has been shown to protect via regulation of apoptosis (Kim et al., 2008; Liu 
et al., 2011) and promotes the hypothesis that caspase activation is necessary in order for 
ipratropium to exacerbate myocardial injury following I/R. However, from other results in this 
study, there is also a necrotic component to the observed ipratropium induced myocyte loss. 
The conditions of oxidative stress, as associated with I/R, lead to loss of mitochondrial 
membrane potential (Hausenloy et al., 2002; Halestrap and Pasdois, 2009). This causes 
primary necrosis due to ATP depletion (Yellon and Hausenloy, 2007) which occurs via the 
resultant collapse of mitochondrial function after disturbance of the mitochondrial membrane 
potential (Crompton, 1999). Cell death via apoptosis can also occur due to outer 
mitochondrial membrane rupture (Hausenloy et al., 2002; Halestrap and Pasdois, 2009). The 
oxidative stress model used in this study measured depolarisation, indicative of loss of 
mitochondrial membrane potential, and also subsequent hypercontracture, rigour contracture 
of myocytes. The results from this model showed that administration of ipratropium 
exacerbated injury following free radical generation as quantified by a reduction in time to 
both depolarisation and hypercontracture. This work provides further evidence that 
ipratropium induces injury via involvement of the mitochondria. Given that Sun et al. (2010) 
indicated that acetylcholine may protect myocardial myocytes from I/R injury via a 
mechanism which stabilises mitochondrial membrane potential (Sun et al., 2010), it is 
possible that the inhibitory effect of ipratropium at muscarinic receptors may prevent this 
action which could lead to the observed exacerbation of myocardial injury. 
In addition, the ability for acetylcholine to significantly increase times to depolarisation and 
hypercontracture indicates that acetylcholine exerts a protective effect via preservation of 
mitochondrial membrane integrity. Indeed, it has been shown that acetylcholine elicits a 
cardioprotective response in I/R via a mitochondrial ATP-sensitive potassium channel which 
assists in the prevention of necrosis and apoptosis via maintenance of mitochondrial 
membrane potential (Sun et al., 2010). The protective properties of acetylcholine observed 
within this study support these observations; as such, the work presented here implies that 
ipratropium is potentially capable of inhibiting the protective properties of endogenous 
acetylcholine. In this study, it was demonstrated that endogenous levels of acetylcholine 
were present in the in vitro models used. However, exogenous elevation of acetylcholine 
was capable of attenuating the ipratropium induced injury. This indicates that the action of 
ipratropium as a competitive antagonist at cardiac muscarinic receptors may play a role in 
the observed ipratropum induced myocardial injury. 
Despite all treatments groups showing significance in comparison with the control group at 
depolarisation, the differences between treatment groups and control were not as marked 
when hypercontracture was measured. Hypercontracture is rigor contracture of myocytes 
due to lack of ATP, however, depolarisation is indicative of loss of mitochondrial membrane 
integrity which may be considered a “point of no return” such that, once this event has 
occurred, cells are committed to death (Baines, 2009). Therefore, although it is interesting 
that the times to hypercontracture vary less among groups, it is the time to depolarisation 
which has determined the fate of the myocytes and ostensibly this is more important as 
following depolarisation the mitochondrion will no longer be capable of producing its own 
ATP, and quickly deplete ATP levels from surrounding, still functioning mitochondria, 
initiating the first, irreversible steps towards a cellular death pathway. In a sense, the time to 
hypercontracture is irrelevant as myocyte death following depolarisation is inevitable.  
These data suggest that ipratropium is capable of eliciting myocardial injury following 
ischaemia/reperfusion by a mechanism which involves disruption of mitochondrial 
membrane potential as well as caspase-dependent apoptosis. 
As muscarinic activation has been shown to protect via the RISK pathway through a 
mechanism which maintains mitochondrial membrane potential, it is possible that the 
antagonist action of ipratropium on muscarinic receptors in the heart may cause involvement 
of phosphoinositide 3-kinase (PI(3)K) and extracellular signal-regulated kinases 1/2 (Erk1/2). 
This may cause deregulation of RISK pathway signalling, however the exact mechanism of 
the pathway remains to be elucidated. 
From a clinical perspective, further investigation is required to identify whether there is a real 
risk for COPD patients with underlying IHD who are receiving anticholinergic drugs. Although 
modern anticholinergics, such as ipratropium, have been favoured due to limited 
bioavailability, 90% of inhaled ipratropium is estimated to be swallowed post administration 
(Cugell, 1986) and the bioavailability is postulated to be approximately 6.9% (Ensing et al., 
1989). This indicates a potential for ipratropium to antagonise muscarinic receptors outside 
the pulmonary system, for example, in the myocardium. Further to this, around 50% of all 
COPD deaths are due to adverse cardiovascular outcomes, with MI remaining the most 
common cause of death in COPD patients (Zielinski et al., 1997; Huertas and Palange, 
2011). It is therefore imperative that further studies are conducted to ascertain whether our 
observations have a clinical implication for COPD patients with underlying IHD. 
To summarise, this work is the first to identify cardiotoxic effects of ipratropium in a non-
clinical setting of myocardial ischaemia/reperfusion. It has been ascertained that a) 
ipratropium exerts its toxic effects via disruption of mitochondrial membrane potential, 
accompanied by an increase in caspase-3 activity and b) the observed ipratropium induced 
toxicity is abrogated by acetylcholine, indicating the observed injury is via potential 
involvement of muscarinic receptor intracellular signalling mechanisms, leading to increased 
myocyte loss via both apoptosis and necrosis. 
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Figure 1 Infarct development in the risk zone after administration of different concentrations 
of ipratropium (1x10-9 M – 1x10-6 M) when administered at the onset of, and throughout, 
reperfusion. Results are presented as infarct/risk ratio (Infarct/Risk %). Expressed as 
arithmetic mean ± SEM. *p<0.05 and **p<0.01 vs. control (51.8 ± 3.0%) n=6. 
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 Figure 2 The effect of 1x10-7 M acetylcholine (ACh) administration at reperfusion on 
ipratropium (1x10-7 M) and atropine (1x10-7 M) induced myocardial injury in the isolated 
perfused rat heart. Results are presented as infarct/risk ratio (I/R%). Mean ± SEM, n=6, 
*p<0.05, **p<0.01 vs. control, $$p<0.01 vs. ipratropium, #p<0.05 vs. Ach, ££p<0.01 vs. 
atropine . 
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Figure 3 Endogenous levels of acetylcholine as determined by choline/acetylcholine assay, 
myocytes at 1x106 cells.ml-1. Panels A and B  Levels of free choline (A, 4.92x10-9 M ± 0.04) 
and total choline (B, 3.41x10-9 M ± 0.03) in normoxic, untreated adult rat ventricular 
myocytes. Panels C and D: Levels of free choline (C, 4.49x10-9 M ± 0.03) and total choline 
(D, 3.16x10-9 M ± 0.02) in untreated adult rat ventricular myocytes subjected to 
hypoxia/reoxygenation protocol. Expressed as arithmetic mean ± SEM, n=5.  
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Figure 4 Assessment of myocyte viability via changes in MTT reductase activity in isolated 
rat ventricular myocytes following hypoxia/reoxygenation. Administration of ipratropium or 
atropine (1x10-11 M – 1x10-4 M) occurred at the onset of, and throughout, reoxygenation. All 
groups were subjected to hypoxia/reoxygenation protocol. Values are mean ± SEM, n=6. 
*p<0.05, **p<0.01 vs. control, n=6. 
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  Figure 5 Effect of acetylcholine ± ipratropium on MTT reductase activity in isolated rat 
ventricular myocytes following hypoxia/reoxygenation, normalised as a percentage of the 
untreated control. Administration of ipratropium (Ip 1x10-7 M), atropine (Atr, 1x10-7 M) and 
acetylcholine (ACh, 1x10-7 M) occurred at the onset of, and throughout, reoxygenation. All 
drug treated groups were subjected to hypoxia/reoxygenation protocol. Values are mean ± 
SEM, n=6. *p<0.05, **p<0.01 vs. control, $p<0.05, $$p<0.01 vs. ACh (1x10-7 M). 
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Figure 6 Assessment of apoptosis and necrosis in adult rat ventricular cardiac myocytes 
following H/R protocol and ipratropium treatment. A and B, original representative flow 
cytometric scatter graphs presenting myocytes subjected to hypoxia and reoxygenation in 
the absence (A) and presence (B) of ipratropium to indicate the differentiation between 
necrotic, apoptotic and viable myocytes. C. Depicts normalised data for apoptotic and 
necrotic myocyte populations expressed as percentage of untreated control. *p<0.05 in 
comparison with respective untreated control, values are mean ± SEM (10,000 myocytes 
recorded per group, n=10) 
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Figure 7 Effect of ipratropium (Ip), atropine (Atr) and acetylcholine (Ach) on cleaved 
caspase-3 levels in ventricular myocytes, following hypoxia and reoxygenation. Ipratropium, 
atropine and acetylcholine administered throughout reoxygenation. A. Original histogram 
depicting cleaved caspase-3 fluroescence (Alexa Fluor 488® conjugate) in myocytes 
following 2 hours hypoxia and exposure to reoxygenation without (-) and with (+) 1x10-7 M 
ipratropium. B. Effect of ipratropium (1x10-9 M – 1x10-6 M) on caspase-3 levels of normalised 
histogram data expressed as percentage of untreated control (white bar). C. Effect of 
acetylcholine (ACh, 1x10-7 M) ± ipratropium (Ip, 1x10-7 M) and atropine (Atr, 1x10-7 M ) on 
levels of cleaved caspase-3 activity in isolated rat ventricular myocytes following 
hypoxia/reoxygenation, as determined by flow cytometric analysis. Expressed as arithmetic 
means, normalised to untreated control, ± SEM, 10,000 myocytes recorded per group,n=6), 
*p<0.05, **p<0.01 vs. respective control. C, #p<0.05, ##p<0.01 vs. ACh (1x10-7 M). 
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Figure 8 Infarct development in the risk zone following Z-DEVD-FMK (7x10-9 M) treatment ± 
ipratropium (1x10-7 M) in isolated perfused rat heart. DEVD and ipratropium both 
administered at the onset of reperfusion. Results are presented as infarct/risk (%).* p<0.05 
(36.7 ± 3.7 (DEVD + ipratropium) and ** p<0.01 (29.7 ± 4.7 (DEVD) and 75.1 ± 4.3 
(ipratropium) vs. control (51.8 ± 3.0, white bar). $$ p<0.01 (36.7 ± 3.7 (DEVD + ipratropium) 
vs. 75.1 ± 4.3 (ipratropium)). There is no significance between the DEVD and DEVD + 
ipratropium groups, Mean ± SEM, n=6.  
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Figure 9 Determination of myocyte depolarisation and hypercontracture as established 
using TMRM loaded cells subjected to laser stimulated oxidative stress generation. Time 
points measured are schematically represented (A) the time to depolarisation, 2nd panel, 
(201.2 ± 9.9 secs) and hypercontracture, 4th panel (585.3 ± 33.9 secs), as visualised by 
confocal microscopy. Effect of ipratropium (1x10-9 M - 1x10-7 M) on time to depolarisation (B) 
and hypercontracture (C). Effect of acetylcholine (ACh, 1x10-7 M) ± ipratropium (Ip, 1x10-7 M) 
on time to depolarisation and hypercontracture (D and E, respectively), values are mean ± 
SEM, n=6 animals, with between 10 and 15 myocytes measured, per animal, for each group. 
*p<0.05, ** p<0.01 vs. respective control (white bars). 
 
  
0
100
200
300
400
500
600
700
Control Ip ACh Ip	  +	  ACh
0
100
200
300
400
500
600
700
Control 1	  nM 10	  nM 100	  nM
0
50
100
150
200
250
Control 1	  nM 10	  nM 100	  nM
Ipratropium	  bromide	  (M)	   Ipratropium	  bromide	  (M)	  
Ti
m
e	  
(s
ec
on
ds
)	  
Ti
m
e	  
(s
ec
on
ds
)	  
A	  
B	   C	  
*	  
*	   *	   *	  
0
50
100
150
200
250
300
350
Control Ip ACh Ip	  +	  ACh
Ti
m
e	  
(s
ec
on
ds
)	  
Ti
m
e	  
(s
ec
on
ds
)	  
D	   E	  
*	  
*	   *	  
**	   **	  
1x10-­‐9	   x10-­‐8	   1x10-­‐7	   1x10-­‐9	   x10-­‐8	   1x10-­‐7	  
Group Infarct/Risk (%)  (Mean ± SEM) 
  
Control 51.8 ± 3.0 
(A)  
Ipratropium bromide:  
1x10-9 M 54.2 ± 1.6 
3x10-9 M 58.3 ± 1.1 
1x10-8 M 61.7 ± 1.9 * 
3x10-8 M 65.3 ± 2.1 ** 
1x10-7 M 75.1 ± 4.3 ** 
3x10-7 M 76.6 ±1.2 ** 
1x10-6 M 76.8 ± 1.1 ** 
(B)  
ACh (1x10-7 M) 42.7 ± 2.9 * $$ 
Ip + ACh (both 1x10-7 M) 57.2 ± 2.0 $$ 
(C)  
Atr (1x10-7 M) 58.6 ± 1.7 *  
Atr + ACh (both 1x10-7 M) 41.8 ± 3.5 * ££ 
 
Table 1 Values for infarct development as expressed graphically in Figures 1 and 3. (A) I/R 
(%) values for isolated perfused rat hearts treated with ipratropium (1x10-9 M – 1x10-6 M). 
Mean ± SEM, *p<0.05,**p<0.01 vs. control. (B) I/R (%) values for isolated perfused rat 
hearts treated with acetylcholine (1x10-7 M) ± ipratropium (1x10-7 M). Mean ± SEM, *p<0.05, 
$$p<0.01 vs. ipratropium (1x10-7 M), ££p<0.01 vs. atropine, n=6 for all groups. 
Group MTT Reductase activity c/w Control (%) (Mean ± SEM) 
  
Control 100 ± 0.0 
  
 Ipratropium bromide: Atropine: 
1x10-11 M 95.1 ± 2.9 * 98.3 ± 8.6  
3x10-11 M 96.2 ± 12.0 97.3 ± 7.8 
1x10-10 M 91.6 ± 14.4 96.6 ± 11.6 
3x10-10 M 91.3 ± 10.7 92.3 ± 6.5 * 
1x10-9 M 79.9 ± 3.0 * 90.2 ± 4.6 * 
3x10-9 M 80.1 ± 7.3 * 93.2 ± 9.1 
1x10-8 M 76.7 ± 3.8 * 88.7 ± 6.9 * 
3x10-8 M 77.0 ± 4.4 * 82.5 ± 6.9 * 
1x10-7 M 69.0 ± 6.2 ** 78.0 ± 8.5 * 
3x10-7 M 72.5 ± 5.1 * 74.4 ± 5.5 * 
1x10-6 M 67.6 ± 5.0 ** 71.1 ± 9.7 * 
3x10-6 M 65.6 ± 9.8 * 76.0 ± 13.5 * 
1x10-5 M 56.6 ± 4.4 ** 73.4 ± 10.2 * 
3x10-5 M 48.7 ± 5.4 ** 69.0 ± 11.2 * 
1x10-4 M 52.7 ± 7.3 ** 68.5 ± 8.0 ** 
 
Table 2 Values for the effect of ipratropium or atropine (1x10-11 M – 1x10-4 M) on MTT 
reductase activity as expressed graphically in Figure 4. Values expressed as a percentage 
of MTT reductase activity in the untreated control group. Mean ± SEM, *p<0.05, **p<0.01 vs. 
control, n=6 for all groups. 
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